Off-Label Prescriptions in Dermatology: Challenges of New Routes of Administration for Certain Old Drugs

被引:1
|
作者
Tasic-Kostov, Marija [1 ]
Ilic, Dusan [1 ]
机构
[1] Univ Nis, Fac Med, Dept Pharm, Nish, Serbia
关键词
off-label drug; dermatology; compounded drugs; drug vehicle; INFANTILE HEMANGIOMAS; TOPICAL PROPRANOLOL; SPIRONOLACTONE; THERAPY; SAFETY; ACNE; GEL;
D O I
10.5937/afmnai37-25282
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
"Off-label drug use" refers to the prescription of medications, with reference to indications, dosage, dosage form, patient group or route of administration, which are officially unapproved. Recently, new indications for some drugs have emerged and few of them are being used off-label to treat topically a variety of dermatological conditions. Off-label use is more common in dermatology than in other medical specialties, and those drugs are basically available as compounded formulations, but the choice of a proper vehicle and safety of extemporaneous drug preparation intended for topical use are usually neglected in case of systemic drugs. Moreover, the bases commonly used as vehicles for extemporaneous dermatological preparations are stabilized with traditional surfactants known for their potential to irritate skin, while inflammatory dermatoses can worsen when exposed to irritants In this paper, we have listed several systemic drugs which are being used in topical treatment of some frequent dermatological conditions, but not according to their officially approved indications. The choice of drugs was made according to the topical off-label dermatological prescriptions obtained from public pharmacies. The aim was also to review data related to, in our opinion, two major drawbacks of using off-label topical drugs: safety data on the use of the final dermal preparation and scientific information relevant for the choice of a proper topical vehicle for specific drug and proper stability evaluation.
引用
收藏
页码:131 / 138
页数:8
相关论文
共 43 条
  • [21] Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
    Spadafora, Marco
    Morsia, Serena
    Di Lernia, Vito Giuseppe
    Kaleci, Shaniko
    Pellacani, Giovanni
    Longo, Caterina
    EXPERIMENTAL DERMATOLOGY, 2025, 34 (04)
  • [22] Off-Label Use of Oncology Drugs: The Need for More Data and Then Some
    Pfister, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 584 - 586
  • [23] Off-label use of cardiovascular drugs as an indicator of therapeutic need in paediatrics
    Cammarata, Silvia Miriam
    Capone, Giacomo
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (02) : 179 - 179
  • [24] Use of off-label nephrology-related drugs in hospitalized pediatric patients: a retrospective study
    Yasinta, Marchella
    Che, Ruo-Chen
    Hu, Cai-Yu
    Du, Xiang-Hui
    Ding, Gui-Xia
    Huang, Song-Ming
    Chen, Ying
    Zhang, Ai-Hua
    WORLD JOURNAL OF PEDIATRICS, 2016, 12 (02) : 236 - 242
  • [25] Comparative Assessment of Off-label and Unlicensed Drug Prescriptions in Children: FDA Versus ANSM Guidelines
    Berdkan, Sandra
    Rabbaa, Lara
    Hajj, Aline
    Eid, Bassam
    Jabbour, Hicham
    El Osta, Nada
    Karam, Latife
    Khabbaz, Lydia Rabbaa
    CLINICAL THERAPEUTICS, 2016, 38 (08) : 1833 - 1844
  • [26] Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System
    Gordon, Noa
    Goldstein, Daniel A.
    Tadmor, Boaz
    Stemmer, Salomon M.
    Greenberg, Dan
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [27] Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina*
    Villalobos, Fernando
    Matellan, Carla
    Sequeira, Gabriel
    Kerzberg, Eduardo
    REUMATOLOGIA CLINICA, 2022, 18 (05): : 286 - 292
  • [28] Off-label intrathecal use of gadobutrol: safety study and comparison of administration protocols
    Merete Halvorsen
    Camilla Sæthre Edeklev
    Jorunn Fraser-Green
    Grethe Løvland
    Svein Are Sirirud Vatnehol
    Øivind Gjertsen
    Bård Nedregaard
    Ruth Sletteberg
    Geir Ringstad
    Per Kristian Eide
    Neuroradiology, 2021, 63 : 51 - 61
  • [29] Off-label intrathecal use of gadobutrol: safety study and comparison of administration protocols
    Halvorsen, Merete
    Edeklev, Camilla Saethre
    Fraser-Green, Jorunn
    Lovland, Grethe
    Vatnehol, Svein Are Sirirud
    Gjertsen, Oivind
    Nedregaard, Bard
    Sletteberg, Ruth
    Ringstad, Geir
    Eide, Per Kristian
    NEURORADIOLOGY, 2021, 63 (01) : 51 - 61
  • [30] Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-label Medications on the Use of Intravitreal Bevacizumab
    Holfinger, Steven
    Miller, Alexander G.
    Rao, Llewelyn J.
    Rowland, Douglas Y.
    Hornik, Joan H.
    Miller, David G.
    JAMA OPHTHALMOLOGY, 2016, 134 (01) : 45 - 48